EUVIMEDEUVIMED entdecken
Crossref

From Site-Specific Conjugation to Linker−Payload Presentation: Lessons from AJICAP and Exo-Linker for Antibody−Drug Conjugate Pharmaceutical Design

Tomohiro Watanabe, Tomohiro Fujii, Yutaka Matsuda

Molecular Pharmaceutics · 10.11.2026

DOI: 10.1021/acs.molpharmaceut.6c00918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 10.11.2026. Verfasst von Tomohiro Watanabe und 2 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic activity and pharmacokinetics of antibody−drug conjugates (ADCs) depend on antibody specificity, payload potency, and the attachment and surface presentation of the linker−payload. Linker−payload presentation denotes the spatial arrangement and local chemical environment of the linker−payload on the antibody. Conjugation site, drug-to-antibody ratio (DAR), release chemistry, and manufacturability are therefore interdependent design variables. This perspective examines AJICAP second-generation site-specific conjugation and Exo-Linker chemistry as approaches to controlling linker−payload presentation. AJICAP enables control of the conjugation site on native immunoglobulin G (IgG) antibodies without antibody sequence engineering, whereas Exo-Linker chemistry illustrates how linker−payload reconfiguration can alter hydrophobic exposure and off-target enzymatic processing. The central argument is that the conjugation site and linker−payload presentation should be evaluated together using orthogonal analytical, pharmacokinetic, stability, and manufacturability readouts. We propose matched site-by-linker comparisons to distinguish these contributions and guide the balance between systemic stability, intracellular release, and manufacturability.

Zitieren

APA

Watanabe, T., Fujii, T., & Matsuda, Y. (2026). From Site-Specific Conjugation to Linker−Payload Presentation: Lessons from AJICAP and Exo-Linker for Antibody−Drug Conjugate Pharmaceutical Design. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00918

Vancouver

Watanabe T, Fujii T, Matsuda Y. From Site-Specific Conjugation to Linker−Payload Presentation: Lessons from AJICAP and Exo-Linker for Antibody−Drug Conjugate Pharmaceutical Design. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00918

BibTeX
@article{Watanabe2026,
  author = {Watanabe, Tomohiro and Fujii, Tomohiro and Matsuda, Yutaka},
  title = {From Site-Specific Conjugation to Linker−Payload Presentation: Lessons from AJICAP and Exo-Linker for Antibody−Drug Conjugate Pharmaceutical Design},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c00918}
}
Kostenlos starten →